Research approves antibiotics for appendicitis

According to final results of the Comparing Outcomes of antibiotic Drugs and Appendectomy (CODA) trial, and an updated treatment guideline for appendicitis from the American College of Surgeons, antibiotics are now an accepted first-line treatment for most people with appendicitis.

The findings of the study were published in the ‘New England Journal of Medicine’.

“In the first three months after taking antibiotics for the condition, nearly 7 in 10 patients in the antibiotic group avoided an appendectomy. By four years, just under 50 per cent had the surgery,” said Dr David Flum, co-principal investigator and professor and associate chair of surgery at the University of Washington (UW) School of Medicine.

“Other outcomes favoured either antibiotics or surgery. Putting it all together, antibiotics look to be the right treatment for many, but probably not all, patients with appendicitis,” added Dr Flum.

CODA is the largest-ever randomised clinical trial of appendicitis treatment. At 25 hospitals across 14 states, 1,552 patients with appendicitis consented to participate and were randomised to receive antibiotics or to undergo an appendectomy.

“While there were advantages and disadvantages to each treatment, we found that both treatments are safe, and patients will likely value these outcomes differ based on their unique symptoms, concerns and circumstances,” Flum said.

Patients with an appendicolith, a calcified deposit found in about 25 per cent of cases of acute appendicitis, were associated with more complications and a higher chance of appendectomy in the first 30 days. At 90 days out, however, there was no greater chance of appendectomy in patients with an appendicolith.

“Given these results and new treatment guidelines, it is important for surgeons and patients to discuss the pros and cons of both surgery and antibiotics in deciding on the treatment that’s best for that person at that time,” said Dr Giana Davidson. She is a UW associate professor of surgery and director of the CODA trial’s clinical coordinating centre.

To foster those conversations, CODA investigators created an online decisionmaking tool for patients. It includes a video (currently in English and Spanish, with other languages to come) and a mechanism to help patients choose a direction that may better suit their individual circumstances.

“In the emergency setting, patients with appendicitis can make a treatment d e c i s i o n h u r r i e d l y, ” Davidson said.

“This online tool was built to help communicate the CODA results in laymen’s terms, and to spur a conv e r s a t i o n b e t w e e n patients and surgeons about potential benefits and harms of each approach,” Davidson concluded.